30/03/2020
Marie Skłodowska-Curie Actions

MSCA-IF: Joint application at the University of Granada. Department of Human Embriology and Anatomy.

This hosting has expired


  • OFFER DEADLINE
    01/07/2020 12:30 - Europe/Brussels
  • EU RESEARCH FRAMEWORK PROGRAMME
    H2020 / Marie Skłodowska-Curie Actions
  • LOCATION
    Spain, Granada
  • ORGANISATION/COMPANY
    International Research Projects Office
  • DEPARTMENT
    Promotion and Advisory Unit
  • LABORATORY
    NA

Professor JOSE CARLOS PRADOS SALAZAR, from the Department of Human Embriology and Anatomy at the University of Granada, welcomes postdoctoral candidates interested in applying for a Marie Skłodowska-Curie Individual Fellowships (MSCA-IF) in 2020 at this University. Please note that applicants must comply with the Mobility Rule (more information: http://sl.ugr.es/0aNV).

Brief description of the institution:

The University of Granada (UGR), founded in 1531, is one of the largest and most important universities in Spain. The UGR has been awarded with the "Human Resources Excellence in Research (HRS4R)", which reflects the UGR’s commitment to continuously improve its human resource policies in line with the European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers. The UGR is also a leading institution in research, located in the top 5/10 of Spanish universities by a variety of ranking criteria, such as national R&D projects, fellowships awarded, publications, or international funding.

UGR is one of the few Spanish Universities listed in the Shanghai Top 500 ranking (http://sl.ugr.es/0aw0). The Academic Ranking of World Universities (ARWU) places the UGR in 268th position in the world and as the 4th highest ranked University in Spain, reaffirming its position as an institution at the forefront of national and international research. From the perspective of specialist areas in the ARWU rankings, the UGR is outstanding in Documentation (ranked in the 36th in the world) or Food science technology (ranked 37th in the world), Mathematics and Computer Science (ranked among the top 76-100 in the world).

The UGR has 4 researchers at the top of the Highly Cited Researchers (HCR) list in the Computer Science area. With regard to broader subject fields, the UGR is ranked in 45th position in the universities worldwide in the discipline of Engineering. It is also well recognized for its web presence (http://sl.ugr.es/0a6i) taking 36th place in the top 200 Universities in Europe. Internationally, we bet decidedly by our participation in the calls of the Framework Programme of the European Union. For the duration of the last two Framework Programmes, the UGR has obtained a total of 66 projects, with total funding of 18.02 million euros, and for H2020, 80 projects with total funding around 20.6 million euros.

Brief description of the Centre/Research Group

The Research Group "New Therapies Applied to Research in Biomedicine" (CTS 107) is a multidisciplinary group with a total of 19 basic and clinical researchers (doctors, clinical oncologists, biochemists, nanotechnologists, biologists, pharmacists, biotechnologists and bioinformatics). Our Group has stable relationship with others Biomedicine and Cancer Centers (Switzerland, UK, Italy and Portugal, among others) and pharmaceutical companies (ROCHE-FARMA S.A and ESTEVE S.L.) and has a clear vocation for clinical application of the results to improve the quality of cancer patient life. Our research activity, continuously funded since 1990, is currently focused on three research lines: 1) New biomarkers for cancer detection, 2) New strategies for cancer treatment: nanotechnology and gene therapy and 3) Cancer and Nutrition. We has obtained relevant achievements published in high impact journals (see results in web), among which we can highlight some that has been patented: 1) to discover new (RNA, proteins and recently metabolites) tumor markers for pancreatic cancer (international patents WO 2014/076342 and WO/2014/198995 and solicited patent P201930559), 2) to determine the application of sigma ligands against cancer (patent WO/2017/21176), 3) to develop of new nanodrugs with doxorubicin and 5-FU in collaboration with the Hospital Virgen de las Nieves which were patented (WO 2012/104461A1 and PCT/ES2014/070941) and 4) to develop for the first time in the world antitumor therapies using the suicide Gef and E genes (WO2015/011332 A1 and W02009/133220).

Project description

Our Project is named BIO-PAN-CAN. Its aim is to use a massive sequencing technique in peripheral blood samples from patients with pancreatic adenocarcinoma (PAD) to determine a sensitive and specific biomarker which can be clinically used to its early detection.

PAD diagnosis usually occurs in an advance stage with the presence of tissue infiltration or metastasis that make the tumour unresectable. In fact, the PAD prognosis is very poor with survival rates of 5% at the first 5 years. In this context, massive sequencing technology allows the simultaneously analysis of thousands of genes in cancer samples in a fast, reproducible and less and less expensive way.

Previous results of our Group demonstrated that the gene expression in peripheral blood of patients with PAD show a different expression pattern from that presented in healthy subjects and that this pattern can be used for its diagnosis. The pattern includes genes such as IRAK3 and CLEC4D (WO/2014/198995). In this ambitious, multidisciplinary (Information Technologies Research Centre and Biomedical Research Centre from Granada) and multicentric Project, five General Hospitals participate to assure the number of samples (peripheral blood) in order to 1) obtain total RNA and carry out RNASeq, 2) analyse big-data and determine pattern of differentially expressed genes; 3) carry out a blind validation study of the differential expression profile by digital PCR, and 4) establish the correlation between proposed markers and clinical-pathological variables of patients with ADP. The success of the Project will allow to obtain a new tool to the ADP early diagnosis that could represent a great clinical advance due to the possibility of starting treatment earlier improving the prognosis of these patients.

Research Area

Information Science and Engineering (ENG) and Life Sciences (LIFE)

For a correct evaluation of your candidature, please send the documents below to Professor JOSE CARLOS PRADOS SALAZAR (jcprados@ugr.es):

  • CV
  • Letter of recommendation (optional)

Disclaimer:

The responsibility for the hosting offers published on this website, including the hosting description, lies entirely with the publishing institutions. The application is handled uniquely by the employer, who is also fully responsible for the recruitment and selection processes.